Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Summary

Homeobox genes are regulatory genes often associated with tumors in the adult organisms. We investigated their comparative expression by immunohistochemical and real-time PCR analysis, in normal and inflammatory nasal mucosae and in sinonasal neoplasms in order to use them as possible diagnostic and therapeutic targets.

Abstract

OTX homeobox (HB) genes are expressed during embryonic morphogenesis and during the development of olfactory epithelium in adult organisms. Mutations occurring in these genes are often related to tumorigenesis in human. No data are available today regarding the possible correlation between OTX genes and tumors of the nasal cavity. The aim of this work is to understand if OTX1 and OTX2 can be considered as molecular markers in the development of nasal tumors. We selected nasal and sinonasal adenocarcinomas to investigate the expression of OTX1 and OTX2 genes through immunohistochemical and real-time PCR analyses.Both OTX1 and OTX2 were absent in all the samples of sinonasal Intestinal-Type Adenocarcinomas (ITACs). OTX1 mRNA was identified only in Non-Intestinal Type Adenocarcinomas (NITACs) while OTX2 mRNA was expressed only in Olfactory Neuroblastomas (ONs). We have demonstrated that the differential gene expression for both OTX1 and OTX2 genes might be a useful molecular marker to distinguish the different types of sinonasal tumors.

Introduction

OTX HB genes are the vertebrate homologue of the Drosophila orthodenticle genes (otd) and they encode for transcription factors which are normally expressed during embryonic morphogenesis, but they can also be expressed in the adult organism with different functions. During embryonic development they control the specification of cell identity, cell differentiation, and the positioning of the body axis¹. The OTX family includes OTX1 and OTX2 genes which display different functions. OTX1 is involved in brain and sensory organ development. In the adult organism, it is expressed in sensory organs and is transcribed at low levels in the anterior lobe of the pituitary gland²; it also plays a role in hematopoiesis, being expressed in hematopoietic pluripotent and progenitor cells³. OTX2 is involved in the development of the rostral head and its translated protein acts as a morphogen because it generates a gradient through which other genes are activated or repressed in a spatio-temporal manner, thus contributing to cell proliferation and differentiation. In the adult organism, OTX2 is found exclusively in the choroid plexus and pineal gland⁴.

Mutations in OTX genes are often related to the appearance of human congenital, somatic, or metabolic defects. Gain or loss mutations in OTX genes could promote tumorigenesis if they are not able to properly control cellular growth and/or differentiation⁵. In leukemias and lymphomas as well as in many solid tumors (e.g., medulloblastomas⁶, aggressive non-Hodgkin lymphomas², breast carcinomas⁷, colorectal cancers⁸, and retinoblastoma⁹), the deregulated expression of OTX HB genes is well documented¹⁰. In addition, OTX2 mutations have been demonstrated in cases of anophthalmia and microphtalmia¹¹ due to the crucial role for this gene in the control of eye development.

In the context of solid neoplasms, the discovery of molecular and phenotypic markers is an important challenge for the diagnosis, classification, and treatment of several types of tumor¹¹, including those that originate in the nasal cavity and paranasal sinuses. In fact, despite that these areas occupy only a modest anatomical space, mucosal epithelium, glands, soft tissues, bone, cartilage or neural/neuroectodermal, and hematolymphoid cells can be often the site for the origin of complex and histologically different groups of tumors. Different types of neoplasms involving the sinonasal tract present a variety of features that overcome what is usually seen in the upper aerodigestive tract or even throughout most parts of the body¹².Sinonasal malignancies are rare and present an annual incidence of 1:100,000 inhabitants worldwide, and so this prevents studies regarding the pathways involved in the tumorigenesis and the testing of alternative treatment strategies.Despite this, the advances in imaging techniques, surgical approaches, and radiotherapy have improved the clinical management of sinonasal cancer.Moreover, the development of cell lines as well as animal models and cancer genetic profiling currently constitute the basis for the future targeted anticancer therapies¹³. To date, there are no reports regarding OTX1 and/or OTX2 expression in neoplasms of the nasal cavity, paranasal sinuses, and nasopharynx. Since we have previously observed that OTX1 and OTX2 are involved in breast cancer⁷, we wondered if these genes could be present not only in the normal nasal mucosa but also in tumors of the nasal cavity. To reach this goal we obtained from the Department of Pathology of the "Ospedale di Circolo" in Varese samples of normal mucosa, and nasal and sinonasal adenocarcinomas collected from 1985 to 2012 and classified according to the World Health Organization (WHO) classification of Head and Neck Tumors. We choose to analyze them through real-time PCR and immunohistochemistry analyses and we evaluated OTX1 and OTX2 expression to determine if they can be considered molecular markers for these types of tumors.

Access restricted. Please log in or start a trial to view this content.

Protocol

All the studies were performed according the Declaration of Helsinki (1975) with written informed consent and approved by the Ethical Committee of the University of Insubria in Varese.

1. Collection of the Samples

1. Collect and divide all the human Formalin-Fixed Paraffin-Embedded (FFPE) samples into different subgroups according the WHO classification of Head and Neck Tumors¹⁴.
   NOTE: Here we used the following samples: Normal sinonasal mucosa as control (10 samples); Inverted Papilloma (IP, ICD-O code 8121/1); Sinonasal ITAC (ICD-O code 8144/3, 32 samples); NITAC (ICD-O code 8140/3, 12 samples); Adenoid Cystic Carcinoma (ACC, ICD-O code 8200/3); Pleomorphic Adenoma (PA, ICD-O code 8941/3); ON (ICD-O code 9522/3, 13 samples); Poorly Differentiated Neuroendocrine Carcinoma (PDNEC, ICD-O code 8041/3, 19 samples); Neuroendocrine Tumor (NET, ICD-O code 8041/3).

2. Immunochemistry

1. Deparaffinization and rehydration of sections
   1. Heat the sample slides in an oven at 60 °C for 30 min and rehydrate 3 µm thick FFPE sections using an alcohol series to water.
   2. Briefly wash the slides in xylene for 10 min and repeat this step; wash the slides for 5 min in 100% alcohol and repeat this step using 95%, 85%, and 75% alcohol serially. Rinse the slides for 5 min in distilled water.
2. Blocking the endogenous activity
   1. Block the endogenous activity by placing the slides in 3% aqueous hydrogen peroxide for 12 min.
3. Antigen retrieval
   1. Perform antigen retrieval by treating with 10 mM Citrate Buffer (pH 6) for 10 min in a microwave treatment.
4. Incubation with primary antibody
   1. Wash the sections in TBS buffer (pH 7.4), then add blocking solution for 10 min.
   2. Wash the sections in TBS buffer (pH 7.4), then add 0.2% Triton X.
   3. Incubate overnight at 4 °C with goat anti-human OTX2 antibody diluted 1:100.
5. Incubation with secondary antibody
   1. Incubate the sections for 1 h at room temperature with biotinylated rabbit anti-goat secondary antibody diluted 1:200 followed by ABC-peroxidase complex (see Tables of Materials).
6. Developing the immunoreaction
   1. Develop the immunoreaction using 3,3'-diaminobenzidine tetrahydrochloride and counterstain the nuclei with Harris Hematoxylin.
7. Mounting and imaging
   1. Dehydrate the sections using a crescent alcohol-scale and clarify them using a clearing substance of terpene origin (see Table of Materials). Embed sections in mounting medium, place the sections on a microscope slide, and observe the sections through an optical microscope.

3. RNA Extraction and Reverse-transcription

1. RNA extraction
   1. Extract RNA from the sections by performing the first step of immunoprecipitation protocol (see section 2.1) and keep the slides in distilled water. Overlap the unstained sections with the corresponding hematoxylin-eosin stained sections in order to identify fragments of interest.
   2. Perform the RNA extraction using a commercial RNA extraction kit for FFPE samples (see Table of Materials) and following manufacturer's instructions.
2. RNA reverse-transcription
   1. Use a commercial kit to retro-transcribe RNA into cDNA (see Table of Materials) following the protocol. Retro-transcribe at least 1,000 ng of total RNA to perform several analyses.

4. Real-time PCR and Data Analysis

1. Real-time PCR
   1. Perform quantitative real-time PCR analyses (qRT-PCR) with probe-based technology (see Table of Materials) and a thermal cycler.
2. Preparation of the PCR reaction mix
   1. Prepare the PCR reaction mix using 12.5 µL of probe-based master mix, 1.25 µL each of OTX1, OTX2, and ACTB probes (see Table of Materials), 50 ng of cDNA, and nuclease-free water up to 25 µL of total volume.
   2. Perform all the reactions in triplicate using the ACTB gene as the endogenous control to normalize gene expression levels.
   3. Centrifuge the plate at 1,109 x g for 3 min and store the plate protected from light at 4 °C until the experiment.
3. Setting the thermal cycler
   1. Set the thermal cycler profile with an initial hot start cycle at 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and a final cycle at 60 °C for 1 min.
4. Gene expression level analyses
   1. Normalize the gene expression levels through the comparative cycle threshold (ΔCt) method using the ACTB gene as the endogenous control.
   2. Evaluate gene expression levels using the 2^-ΔCt method and plot the results.
5. Statistical analyses
   1. Perform statistical analyses using Student's t-Test, considering statistically significant results with p < 0.05.

Access restricted. Please log in or start a trial to view this content.

Results

In the normal mucosa we observed strong and homogenous nuclear reactivity for OTX genes both in the ciliated pseudostratified respiratory-type epithelium and in the submucosal glandular cells (Figure 1A). We found nuclear expression for OTX1 in all NITACs samples (Figure 1B), while little or absent immunoreactivity was highlighted in ITACs (Figure 1C). Intense immunoreactivity was present in all ONs ...

Access restricted. Please log in or start a trial to view this content.

Discussion

This study shows for the first time that, based on mRNA levels, the HB genes OTX1 and OTX2 are expressed in normal sinonasal mucosa and submucosal glands, inflammatory polyps, sinonasal Schneiderian papillomas, and in the different epithelial and neuroectodermal neoplasms, including squamous carcinomas, non-intestinal type sinonasal adenocarcinomas, salivary gland-type tumors, neuroendocrine neoplasms, and ONs.

Modifications and Troubleshooting:

To avoid RNA degradatio...

Access restricted. Please log in or start a trial to view this content.

Materials

Name	Company	Catalog Number	Comments
RecoverAll Total Nucleic Acid Isolation	Applied Biosystem	AM1975
High-Capacity cDNA Reverse Transcription Kit	Applied Biosystem	4368814
TaqMan Universal PCR Master Mix, no AmpErase UNG	Applied Biosystem	4326614
ABI Prism 7000	Applied Biosystem	270001857
ACTB probe	Applied Biosystem		Out of production. Sequence protected by copyright
OTX1 probe	Applied Biosystem		Out of production. Sequence protected by copyright
OTX2 probe	Applied Biosystem		Out of production. Sequence protected by copyright
Acqueous Hydrogen Peroxide	Merk	1072090250
Citrate Buffer	Sigma-Aldrich	20276292
Triton	Sigma-Aldrich	101473728
Tris	Merk	108382
NaCl	Merk	106404
Goat Anti-OTX2 Antibody	Vector Laboratories		Out of production. Catalog number not available
Rabbit Anti-Goat Antibody	Vector Laboratories	BA5000
ABC-Peroxidase Complex	Vector Laboratories	PK6100
3,3'-diaminobenzidine tetrahydrocloride (DAB)	Sigma-Aldrich	D5905
Harris Hematoxylin	Bioptica	0506004/L
Pertek	Kaltek SRL	1560
BioClear	Bioptica	W01030799